MedTrace Logo

Removal of T Cells to Prevent Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation

NCT00005641 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2012-12-11

No results posted yet for this study

Summary

RATIONALE: Bone marrow transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy used to kill tumor cells. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Eliminating the T cells from the donor cells before transplanting them may prevent this from happening.

PURPOSE: Phase II trial to study the effectiveness of T cell removal to prevent graft-versus-host disease in patients who are undergoing bone marrow transplantation from a donor.

Conditions

Interventions

BIOLOGICAL

anti-thymocyte globulin

DRUG

busulfan

DRUG

cyclophosphamide

DRUG

cyclosporine

DRUG

leucovorin calcium

DRUG

methotrexate

DRUG

methylprednisolone

PROCEDURE

allogeneic bone marrow transplantation

PROCEDURE

in vitro-treated bone marrow transplantation

RADIATION

radiation therapy

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • H. Lee Moffitt Cancer Center and Research Institute

    lead OTHER

Principal Investigators

  • Steven C. Goldstein, MD · H. Lee Moffitt Cancer Center and Research Institute

Study Design

Purpose
TREATMENT

Eligibility

Min Age
15 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1997-09-30
Primary Completion
2000-09-30
Completion
2000-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00005641 on ClinicalTrials.gov